PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Hindawi Pub. Co.
    • Subject Terms:
      Databases, Nucleic Acid* ; Endometrial Neoplasms*/genetics ; Endometrial Neoplasms*/immunology ; Gene Expression Profiling* ; Neoplasm Proteins*/genetics ; Neoplasm Proteins*/immunology ; Programmed Cell Death 1 Receptor*/genetics ; Programmed Cell Death 1 Receptor*/immunology; Gene Expression Regulation, Neoplastic/*immunology ; Gene Regulatory Networks/*immunology; Computational Biology ; Female ; Humans
    • Abstract:
      Gynecological malignancies are tumors of the female reproductive system, mainly cervical cancer, endometrial cancer, and ovarian cancer. Endometrial cancer (EC) is the most common gynecological malignant tumor in developed countries. The aim of this study was to construct a network of programmed cell death protein 1 (PD-1) coexpressed genes through bioinformatics analysis and screen the potential biomarkers of PD-1 in endometrial cancer. In addition, genes and pathways involved in PD-1 and modulating tumor immune status were identified. We select the EC transcriptomic dataset in TCGA to retrieve gene sets on the cBioPortal platform, and the PD-1 coexpressed genes were obtained on the platform. GO and KEGG enrichment analysis of coexpressed genes was performed using the DAVID database. The target protein-protein interaction (PPI) network was constructed using Cytoscape 3.7.1 software, and the hub genes were then screened. A total of 976 coexpression genes were obtained. The enrichment analysis showed that PD-1 coexpressed genes were significantly enriched in overall components of the cell structure, the interaction of cytokines with cytokine receptors, chemokine signaling pathways, and cell adhesion molecules (CAMs). Ten hub genes were obtained by node degree analysis. CD3E gene is involved in the prognosis and immune process of EC, and the expression level is related to PD-1 (Pearson correlation coefficient is 0.82, P < 0.01). Patients with low CD3E gene expression in EC have a poor prognosis. The coexpression hub genes of PD-1 are related to immunity, in which CD3E is a prognostic marker that is involved in the PD-1/PD-L1-induced tumor immune escape. This study provides a new area to study the mechanism of PD-1/PD-L1 in EC and the precise treatment with targeted drugs.
      Competing Interests: The authors declare that they have no competing interests.
      (Copyright © 2021 Lina Wang et al.)
    • References:
      Oncoimmunology. 2015 Aug 12;5(1):e1069937. (PMID: 26942091)
      Oncotarget. 2017 Jun 8;8(34):57826-57835. (PMID: 28915714)
      Clin Cosmet Investig Dermatol. 2017 Aug 24;10:325-339. (PMID: 28883738)
      Clin Ther. 2015 Apr 1;37(4):764-82. (PMID: 25823918)
      PLoS One. 2016 Oct 27;11(10):e0165395. (PMID: 27788220)
      Adv Gerontol. 2015;28(3):453-461. (PMID: 28509480)
      Nat Commun. 2018 Aug 10;9(1):3196. (PMID: 30097571)
      Bioinformatics. 2012 Jul 1;28(13):1805-6. (PMID: 22543366)
      Chin J Cancer. 2014 Sep;33(9):434-44. (PMID: 25189716)
      Cancer Immunol Res. 2017 May;5(5):408-416. (PMID: 28408386)
      J Exp Med. 2017 Sep 4;214(9):2715-2732. (PMID: 28838952)
      Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368. (PMID: 27924014)
      Oncotarget. 2019 Jul 16;10(44):4532-4545. (PMID: 31360302)
      N Engl J Med. 2015 Nov 5;373(19):1803-13. (PMID: 26406148)
      J Thorac Oncol. 2018 Apr;13(4):521-532. (PMID: 29269008)
      Science. 2018 Feb 16;359(6377):801-806. (PMID: 29301960)
      Mol Neurobiol. 2018 Aug;55(8):7072-7078. (PMID: 29383686)
      Gynecol Oncol. 2017 Jun;145(3):446-452. (PMID: 28347512)
      Front Pharmacol. 2017 Aug 23;8:561. (PMID: 28878676)
      J Clin Pathol. 2018 Mar;71(3):189-194. (PMID: 29097600)
      Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
      J Clin Invest. 2004 Nov;114(10):1512-7. (PMID: 15546002)
      Cold Spring Harb Perspect Biol. 2018 Sep 4;10(9):. (PMID: 29038115)
      J Immunother. 2019 Feb-Mar;42(2):51-54. (PMID: 30247204)
      J Immunother Cancer. 2017 Aug 15;5(1):62. (PMID: 28807004)
      Oncoimmunology. 2014 Dec 21;3(11):e963413. (PMID: 25914862)
      J Clin Oncol. 2017 Aug 1;35(22):2535-2541. (PMID: 28489510)
      Cancer Treat Rev. 2018 Feb;63:122-134. (PMID: 29287242)
      Onco Targets Ther. 2017 Mar 14;10:1561-1573. (PMID: 28352189)
      Oncotarget. 2017 Apr 6;8(31):51024-51036. (PMID: 28881626)
    • Accession Number:
      0 (Neoplasm Proteins)
      0 (PDCD1 protein, human)
      0 (Programmed Cell Death 1 Receptor)
    • Publication Date:
      Date Created: 20210614 Date Completed: 20210922 Latest Revision: 20240402
    • Publication Date:
      20240402
    • Accession Number:
      PMC8172290
    • Accession Number:
      10.1155/2021/9923434
    • Accession Number:
      34124265